Newly Approved and Investigational Drugs for Motor Symptom Control in Parkinson's Disease

Daniel Garbin Di Luca, Nikolai Gil D. Reyes, Susan H. Fox

Research output: Contribution to journalArticlepeer-review

8 Scopus citations

Abstract

Motor symptoms are a core feature of Parkinson’s disease (PD) and cause a significant burden on patients’ quality of life. Oral levodopa is still the most effective treatment, however, the motor benefits are countered by inherent pharmacologic limitations of the drug. Additionally, with disease progression, chronic levodopa leads to the appearance of motor complications including motor fluctuations and dyskinesia. Furthermore, several motor abnormalities of posture, balance, and gait may become less responsive to levodopa. With these unmet needs and our evolving understanding of the neuroanatomic and pathophysiologic underpinnings of PD, several advances have been made in defining new therapies for motor symptoms. These include newer levodopa formulations and drug delivery systems, refinements in adjunctive medications, and non-dopaminergic treatment strategies. Although some are in early stages of development, these novel treatments potentially widen the available options for the management of motor symptoms allowing clinicians to provide an individually tailored care for PD patients. Here, we review the existing and emerging interventions for PD with focus on newly approved and investigational drugs for motor symptoms, motor fluctuations, dyskinesia, and balance and gait dysfunction.

Original languageEnglish
Pages (from-to)1027-1053
Number of pages27
JournalDrugs
Volume82
Issue number10
DOIs
StatePublished - Jul 2022

Fingerprint

Dive into the research topics of 'Newly Approved and Investigational Drugs for Motor Symptom Control in Parkinson's Disease'. Together they form a unique fingerprint.

Cite this